Objective: Chronic kidney disease patients are characterized by impaired physical function. The goal of exercise-based interventions is an improvement in functional performance. However, improvements are often determined by "statistically significant" changes. We investigated the "minimum clinically important difference," "the smallest change that is important to the patient," for commonly reported physical function tests. Design: Nondialysis chronic kidney disease patients completed 12-wks of a combined aerobic (plus resistance training). The incremental shuttle walking test, sit-to-stand 5 and 60, estimated 1-repetition maximum for the knee extensors, and VO 2peak were assessed. After the intervention, patients rated their perceived change in health. Both anchor-and distribution-based minimum clinically important difference approaches were calculated. Results: The minimum clinically important difference was calculated as follows: incremental shuttle walking test, +45 m; sit-to-stand 5, −4.2 secs; VO 2peak , +1.5 ml/kg per min. Because of comparable increases in "anchor" groups, no minimum clinically important difference was estimated for the sit-to-stand 60 or estimated 1-repetition maximum. Conclusions: We have established the minimum clinically important difference in chronic kidney disease for common tests of physical function.
C hronic kidney disease (CKD) is the progressive loss of renal function and is associated with premature mortality, multimorbidity, and reduced quality of life. 1, 2 Chronic kidney disease is a global health burden estimated to affect between 11% and 14% of people worldwide. 2 With an economic cost of more than US $60 billion per year, 3 14% of the United States and Canada population have moderate to severe CKD stage 3 to 5, with this rising to 25% in those 60 yrs and older. 2, 3 Patients with CKD are characterized by impaired physical functioning and limited exercise capacity, which can further result in reduced health-related quality of life and poor clinical outcome. 4 The pathological mechanisms behind this reduction in physical function and exercise capacity are complex and multifactorial. Potential factors include wasting of the skeletal muscle, inflammation, endothelial dysfunction, anemia, and inactivity. [5] [6] [7] Many of these factors are "modifiable" and, as such, may be improved or corrected through successful intervention. Exercise rehabilitation is becoming an increasing important tool to help improve exercise capacity and functional performance in CKD, 6, 8 and a number of research studies have found favorable effects of exercise in this patient group. 5, 7, [9] [10] [11] A frequently reported outcome measure in rehabilitation research is VO 2peak , 11, 12 a measure of maximal aerobic capacity. VO 2peak is obtained during a cardiopulmonary exercise test and is regarded as the "gold standard" measure of exercise capacity. Another key outcome is muscular strength. In CKD, where lower limb muscles are often atrophied, 10 strength interventions and testing are particularly important. Consequently, estimating maximum strength using resistance machines has previously been used as a valid measure of strength and may be more applicable in nonlaboratory settings where dynamometry is not available. 13 Though more accurate, graded maximal laboratory exercise tests and progressive strength testing may be impractical in some rehabilitation or clinical research settings. Consequently, pragmatic "field" tests of physical function and performance are also used. These include the "incremental shuttle walking test" (ISWT), 14 to assess exercise capacity, and various chair "sit-to-stand" (STS) tests (e.g., 5-repetition, repetitions in 60 secs; STS-5/60) to assess dynamic balance, lower body strength, and, in the case of the STS-60, muscle endurance. 15, 16 All of these tests are extensively used in a wide range of clinical populations including older adults, 17, 18 chronic obstructive pulmonary disease, 15, 19 heart transplant patients, 20 Parkinson disease, 21 and CKD 10, 16, 22, 23 to assess outcomes after various interventions.
Undeniably, the goal of many therapeutic interventions, such as exercise programs, is an improvement in functional performance. Unfortunately, "real" improvements in clinical research trials are often decided by "statistically significant" changes. Describing the limitations of significance testing is beyond the scope of this article (for further reading, see the American Statistical Association 2016 position statement 24 ); however, a statistically significant change merely indicates that a result did not occur by chance and may have no translation into a useful recognized benefit to the patient. [25] [26] [27] The concept of the "minimum clinically important difference" (MCID) was first developed in 1989 28 and is defined as "the smallest change that is important to the patient." Described as "fundamental to all clinical trials," 29 the MCID constitutes a threshold for outcome scores over which a patient would consider meaningful 25, 30, 31 and is important in determining the "clinical effectiveness" of an intervention.
The MCID is preferably estimated using an "anchor"-based approach. Here, an external criterion, or "anchor," is matched with an outcome of interest (e.g., outcome measure score). Often this "anchor" is a patient-reported subjective Likert scale with varying degrees of changes (e.g., "good" through to "bad"). 25, 26 Alternatively, statistical driven "distribution" methodology can be used. These methods do not require patient input but use estimations of outcome variability (e.g., standard deviation [SD] or effect size) to estimate an MCID.
No MCIDs currently exist for the commonly reported physical function tests mentioned previously in a nondialysis CKD population. However, because exercise rehabilitation and interventions are increasingly being used to overcome functional deficits in CKD, 8 establishment of the MCID for such tests would aid healthcare professionals and researchers to interpret improvements from a patient perspective after the implementation of a particular intervention. This may be particularly beneficial in determining the clinical effectiveness in individual patients or in studies with small sample sizes. In addition, the MCID has implications for the design of clinical trials, in terms of sample size calculation and the selection of endpoints. 31 
AIMS
The aim of this study was to calculate an MCID for the ISWT, STS-5/60, estimated 1-repetition maximum (e1RM), and VO 2peak , by both anchor-and distribution-based methods, using a 12-wk exercise program as the therapeutic intervention in nondialysis CKD. A secondary aim was to observe the agreement between the patient-reported (anchor) and statistical (distribution) methods.
METHODS

Design, Setting, and Patients
This was a retrospective secondary analysis of a study investigating the effects of a 12-wk combined aerobic and resistance training intervention in nondialysis CKD patients conducted at the Leicester General Hospital, UK between December 2013 and October 2016. Patients gave written informed consent and national research ethics committee approval was obtained.
To be eligible for this study, participants (a) were diagnosed with moderately severe CKD (stages 3b-5); (b) were 18 yrs and older; (c) had no physical impairment or significant co-morbidities that were a contraindication to exercise (unstable hypertension, potentially lethal arrhythmia, uncontrolled diabetes mellitus (glycated hemoglobin >9%)); and had sufficient command of English to give informed consent. Patients were excluded if they began any form of renal replacement therapy (e.g., dialysis) or developed any physical impairment or significant co-morbidities that were a contraindication to exercise (as described previously). The patient's clinician had the final decision on their inclusion to the study. The inclusion/exclusion criteria were kept broad to maximize recruitment rates and allow as many patients as possible the opportunity to take part in the intervention.
Renal Exercise Rehabilitation Intervention
A full description of the methods for this study can be found in Watson et al. 32 Patients attended Leicester Diabetes Centre, a UK exercise gym, three times a week for 12-wks. Based on current cardiac and pulmonary rehabilitation principles, the exercise consisted of either moderate to vigorous aerobic only (70%-80% of heart rate maximum, 30-min duration) performed on standard cardiovascular training equipment (e.g., treadmill, cycle ergometer, rowing machine) or a combined aerobic (as above but for 20-min duration) plus resistance training (70% 1RM 3 sets of 10-12 repetitions) on a leg extension and leg press machine. Lower limb muscle exercises were chosen because of their prominent role in functional ability (e.g., walking, getting out of a chair) and proneness to muscle atrophy. 33 Patients gradually built up to the required intensities if they could not attain them at the start of the program. For the purpose of this analysis, both groups (aerobic and aerobic plus resistance) are combined together to increase sample number.
Outcome Measures
On initial assessment, basic anthropometric variables (height and weight) and medical history were taken. Current kidney function (estimated glomerular filtration rate [eGFR]) (ml/min/1.73 m 2 ) was taken from the patient's latest routine blood samples.
The ISWT was used as a measure of exercise capacity and cardiorespiratory fitness. 14, 34 For this test, the patient was required to walk between two cones 10 m apart. Patients maintained a speed regulated by an external auditory beep. The walking speed was initially very slow (0.5 m/sec), but for every minute stage, the required walking speed increased by 0.2 m/ sec. The patient maintained cadence with the beeps until volitional exhaustion or until they could no longer keep up with the required pace. The total number of shuttles and distance walked (meter) was calculated. Patients completed a familiarization of the ISWT before their assessment visit.
The STS-5 and STS-60 tests were used as measures of lower body strength, balance, and muscle endurance. For these tests the patient sat on a seat (17 inches [43.2 cm] from the ground) with their feet slightly apart. With their hands across their chest, patients were asked to (1) perform 5 STS cycles as fast as possible 19 and (2) perform as many STS cycles in 60 secs. 16 The maximal strength (kilogram) of the quadriceps muscle was measured using a leg extension machine (TechnoGym, Italy). Performing a true 1RM test is associated with an increased injury risk and stress on the muscles and joints, particularly in untrained 13 and clinical groups 35 ; therefore, we estimated 1RM (e1RM) of the knee extensors from a 5-rep maximum. 36 During the test, weight was progressively increased in 2.5 kg increments, and the 5-rep maximum was determined as the maximal weight the patient could lift five times with correct technique.
Peak exercise capacity (VO 2peak ) was assessed using cardiopulmonary exercise test. Patients were asked to cycle for as long as possible at 60 or more revolutions per minute (RPM). After a 3-min warm-up, the resistance on the static ergometer (Lode Excalibur, the Netherlands) increased from 30 watts by 1 watt every 3 secs in a ramp protocol. Throughout the test, an electrocardiogram was reviewed by an exercise cardiac nurse or doctor. The test was terminated if RPM is less than 60 and was unable to be increased with encouragement; the patient reached volitional exhaustion; or at the discretion of the medical professional. Oxygen consumption was measured using directly using an online breath-by-breath system (Cortex Metalyzer, Cranlea, United Kingdom) and relative VO 2peak (peak milliliter per kilogram per minute) calculated.
All outcome measures had a familiarization test to reduce learning effects 37, 38 and were completed pre-exercise and postexercise intervention.
Anchor-Based MCID
Immediately after completion of the 12-wk exercise intervention, patients were asked to rate how much they felt that their health had changed using the Medical Outcomes Short Form 36 questionnaire: "My health is… than 1 yr ago" (i.e., before commencement of exercise intervention). Responses were categorized on a five-point Likert scale as follows: (a) "much better"; (b) "somewhat better"; (c) "about the same"; (d) "somewhat worse"; and (e) "much worse."
As described previously, response (b) (i.e., for patients to perceive their health as "somewhat better") was used as the minimum MCID threshold, 39 and for ease of interpretation, patient responses were grouped into two categories: "better" (responses a + b) and "the same or worse" (responses c + d + e). Similar grouping has been performed previously. 40 
Distribution-Based MCID
Two distribution-based methods were used:
1. SD method = 0.5 Â the SD of the change score (pre-post exercise) 25 ; 2. Effect size method = change in scores corresponding to a small effect size (0.2) (0.2 Â the mean change score). 26 
Statistical Methods
Because this was a secondary analysis, no a priori sample size was calculated for the outcomes reported here. Only data for patients (n = 26) who completed the postintervention questionnaire were included. The baseline variables were normally distributed. The change in physical function scores achieved by patients for each response category of the anchor-based approach is reported as the mean (with 95% confidence intervals [95% CI]). Because baseline performance may impact upon the change in physical function achieved, 39, 40 mean percentage change was calculated to adjust for baseline values. Parametric independent sample t tests were used to investigate the differences between groups, whereas within-group changes were a 96% of patients were CKD stage 3b to 4, only 1 person had an eGFR of <15 (i.e., CKD stage 5); however, she was not treated using a renal replacement therapy.
IgA, immunoglobulin A.
assessed using paired sample t tests. Data were analyzed using SPSS 24 (IBM UK Ltd, United Kingdom). Statistical significance was set at P < 0.050.
RESULTS
Patients
Of the 54 patients consented to the main trial, 41 completed the 12-wk exercise program. Of these, 26 patients completed the Short Form 36 questionnaire postexercise and were eligible for analysis. Baseline characteristics for these 26 patients are found in Table 1 . Most patients (96%) were CKD stage 3b to 4. One patient had an eGFR of 8 ml/min/1.73 2 (i.e., CKD stage 5), although she did not require any modality of renal replacement therapy.
Summary of Main Effects of Renal Rehabilitation Program
Adherence to the exercise program was good with an average of 31/36 (86%) sessions attended. Most patients achieved the target intensity in the first session. For the aerobic component, 85% of patients reached their heart rate % target and goal duration (minutes) in the first session. All patients had reached the required intensity for the aerobic component by the end of week 2 (i.e., by session 6). For the resistance component, 60% reached the required 70% 1RM goal in the first session. Apart from 3 patients (whom all achieved desired intensity by week 6), the rest of the patients reached 3 sets of 10-12 repetitions (70% 1RM by week 2/session 6).
In this subgroup (n = 26), 12-wk exercise training had favorable effects on physical function. Mean distance walked on the ISWT increased by +32 m (95% CI = 5 to 58, P = 0.021); the number of seconds taken to complete the STS-5 was reduced by −3.1 secs (95% CI = 1.1 to 5.0, P = 0.004); and the number of repetitions on the STS-60 increased by +4 (95% CI = 2 to 7, P = 0.001). Estimated 1RM increased by +18.7 kg (95% CI = 13.1 to 24.4, P < 0.001). VO 2peak increased by +1.3 ml/kg per min (95% CI = −0.2 to 2.8), although this was not significant (P = 0.112).
Most patients (17/26, 65%) rated their health as "better" on the Short Form 36 questionnaire, whereas 7 (27%) patients felt that it was the "same" and 2 (8%) rated it as "worse." As such, 9 (35%) patients felt that their health was "same or worse."
Anchor-Based MCID
The mean (SD) age of the "better" group was 62.4 (14.6), whereas the "same or worse" group was 59.4 (13.1) (P = 0.616). There was no difference in the number of females in each group (9 vs. Using anchor-based analysis, there were small yet distinct differences in outcome measure changes between those who rated their health as "better" versus those who rated their health as the "same or worse" after the exercise program (Table 2 ).
In the ISWT, patients who rated themselves as "better" significantly increased their distance walked by 45 m (P = 0.033). In comparison, those who rated themselves as the "same or worse" increased by 26 m (P = 0.339). The time taken to complete the STS-5 was reduced by 4.2 secs in the "better" patients (P = 0.007) compared with −0.9 secs (P = 0.221) in the "same or worse" group. This difference of 3.3 secs was significant (P = 0.041). VO 2peak was increased in both groups, although the greater improvement was seen in the "better" patients (1.5 ml/kg per min, P = 0.073), compared with just 0.5 ml/kg per min (P = 0.788) in the "same or worse" patients. Improvements in the STS-60 and e1RM were comparable between the groups. As both groups significantly increased at comparable rates, estimates of the MCID (i.e., using the mean improvement for the "better" group) are inconclusive.
SD method, MCID = 0.5 Â the SD of the change score (pre-post exercise); effect size method, MCID = 0.2 Â the mean change score (pre-post exercise). Table 3 shows MCID estimates using distribution-based methodology. The SD method yielded values closest to those estimated using the anchor-based approach. For VO 2peak , the MCID estimated was greater than that calculated using the anchor method (1.5 vs. 1.8 ml/kg per min). The MCIDs calculated using the effect size method were considerably lower than using an anchor-based method.
Distribution-Based MCID
DISCUSSION
After 12-wks of supervised exercise, we have been able to identify the MCID for several common measures of physical function. The MCID estimated in the current trial for the ISWT is 45 m (11%) and is the first reported in a nondialysis CKD population. This value compares well with previous estimates in chronic obstructive pulmonary disease patients after 7-wk pulmonary rehabilitation (48 m/28%) 34 and patients with idiopathic pulmonary fibrosis after pulmonary rehabilitation (46 m/17%). 40 The MCID in patients after 6-wk cardiac rehabilitation was slightly greater at 70 m (18%) 39 ; however, although in absolute terms our improvement of 45 m is 25 m less than that described in this study, the baseline ISWT distance in that trial (391 m) was less than that seen in our cohort (420 m). As such, patients with a lower baseline score may "have more to gain" 39 and when normalized to a percentage change, the disparity is somewhat reduced (11% vs. 18%). Furthermore, disease-specific limitations may also contribute to the disparities seen.
A valid MCID should be at least as large as the observed "minimal detectable change" (MDC). 26 The MDC is the smallest amount of reliable change in a measurement necessary to conclude that the difference is not attributable to error. Change exceeding the MDC is considered "true" change. 41 Our MCID change value of 45 m seen in the "better" group (and the absolute difference between the "better" and "same or worse" group: 19 m) exceeds the MDC for the ISWT in CKD. 42 As such, this change cannot be attributed to the inherent error of the ISWT.
The mean change in our "same or worse" group for the ISWT (26 m) was similar to that in seen in chronic obstructive pulmonary disease 39 where the "about the same" group increased by 29 m. This demonstrates that patients failed to rate, positive yet, small changes in exercise capacity. This may be a consequence of a "response shift" in which contact with a health professional shifts a patient perspective on how they assess current state. 39 It may also be that an increase of 26 m is simply insufficient to have a noticeable effect on self-perceived health in CKD and that greater improvements (i.e., 45 m) are required to have noticeable benefits to the patients.
We estimated the MCID for the STS-5 test at −4.2 secs (−33%). Notably, this was significantly different than the −0.9 secs (−7%) in the "same or worse" group. Our MCID value, and the difference between groups, exceeds the MDC for the STS-5. 42 Previous estimates of an MCID in the STS-5 test are scarce. Jones et al. 15 previously valued the MCID as a reduction of −1.7 secs (−11%) after pulmonary rehabilitation, whereas Meretta et al. 43 estimated it at −2.3 secs in patients with peripheral, central, or mixed vestibular dysfunction after an individualized outpatient vestibular rehabilitation program. 43 Using a distribution-method approach, the MCID was estimated at −3.7 secs (−27%) in patients with multiple sclerosis. 44 We found that an improvement of 1.5 ml/kg per min (7%) in VO 2peak was sufficient for patients to detect a positive change in their health. This value exceeds the MDC for the VO 2peak . 42 Despite being a frequently reported outcome in clinical research, there is limited analysis into the MCID for maximal oxygen uptake (measured as either VO 2peak or VO 2max ). In 17 elderly patients with abdominal aortic aneurysms undergoing 6 wks of supervised exercise (2Â/wk), the MCID was defined as an improvement of 2.0 ml/kg per min (19%). 45 Although MCID data are limited for changes in maximal aerobic capacity, any improvements should not be understated. In a large meta-analysis, Kodama et al. 46 found an improvement of 1-MET (3.5 ml/kg per min) resulted in a 13% reduction in all-cause mortality and 15% reduction in cardiovascular disease-related events (in healthy men and women). Furthermore, Myers et al. 47 reported each 1-MET increase in exercise capacity conferred a 12% improvement in survival in elderly men referred for clinical treadmill exercise testing. Our overall improvement of 1.3 ml/kg per min equates to 0.37-MET (and extrapolated could mean a~5% reduction in all-cause mortality based on previous research).
After 12 wks of exercise, we found that performance in the STS-60 and e1RM tests were both increased. When separating patients into our MCID "anchors" (i.e., "better" or "same or worse"), we found that both groups increased at comparable rates. As such, we could not distinguish an obvious MCID value for these tests. Notably, the difference (1 repetition) between the "better" and "same or worse" groups for the STS-60 did not exceed the MDC for this test, and thus, the difference observed could be a result of natural test variation. Although explanations for absence of a clear MCID for the STS-60 and e1RM are unknown, it may be that a greater improvement is needed for patients to perceive this as having a positive effect on their health. Tests such as the ISWT or STS-5 have more transferable application to everyday activities (e.g., walking, standing up from a chair several times). Conversely, performing approximately 30-70 STS repetitions (as seen in the STS-60) may not seem useful or relevant, and because of the duration of the test, patients may be unable to comprehend the somewhat small improvements seen. For the e1RM, it is unlikely patients would repeat this movement in everyday life, and though a good measure of strength, it is localized to the quadriceps. More overall lower limb strength measures may have a greater influence on patients.
Anchor Versus Distribution Methodology
We used two statistically driven distribution approaches of estimating the MCID: the effect size and SD method. These methods do not require a subjective patient input but use estimations of outcome variability. We observed that overall, these methods markedly underestimated the MCID when compared with favored anchor-based estimates. The exception to this was the MCID for VO 2peak , which was estimated by the SD approach at 1.8 ml/kg per min compared with the anchor-based method estimate of 1.5 ml/kg per min. Similar discordance between distribution-and anchor-based approaches have been observed previously.
In particular, the effect size method severely underestimated MCID values. The change in scores corresponding to a small effect size (0.2) has previously been considered the MCID. 26 However, our patients may have higher expectations of what constitutes a "better" quality of life after an intervention such as exercise. Consequently, estimating the MCID using a large effect size (>0.8) may be more appropriate. Although potentially useful in estimating the MCID when an anchor-based method is not available (no subjective quality of life criterion measured) or unachievable (as in the case of the STS-60 and e1RM in our trial), this approach (i.e., using a statistically driven methodology) ignores the very purpose of the MCID because it does not address the question of clinical importance and, importantly, fails to distinctly separate clinical importance from statistical significance. 26 
Strengths and Limitations
The strength of this study is that it a uses patient-centered approach to determine the MCID. However, because an anchor-based approach relies on retrospective estimates of health, 34 this approach is at risk of interference by "recall bias" as patients are required to remember the intrinsic nature of their condition before an intervention. 26, 27 Our analysis is limited by a small opportunistic sample size. This restricts the analysis in two aspects. Firstly, although some of our data are comparable with previous estimates from other clinical populations, it should be further substantiated in larger cohorts. Unfortunately, complex exercise interventions in research are difficult to perform, especially in CKD groups, and thus our data do provide useful and important preliminary data in this regard. Secondly, because of a reduced number of patients, we combined both groups of exercise modalities. This prevents differentiation of MCIDs for these interventions. However, it should be noted that changes in VO 2peak , ISWT, STS-5, and STS-60 performance were similar (i.e., no significant differences) between the two groups in the full analysis. Thus, it appears for these tests, 12-wk exercise of any modality is sufficient to improve performance. Unsurprisingly, the only difference in performance observed between the two groups was seen for e1RM (the additional resistance arm increased by 13 kg more); interestingly, e1RM was one of the variables we were unable to ascertain a MCID for. A small sample size also meant that only 9 (35%) patients identified their health as "the same or worse" (two of these felt it got "worse"). Although this clearly shows positive benefits of exercise in this group (i.e., improving health and/or preventing further decline), it limits the generalisability of the findings. Lastly, our resistance program contained only two lower limb resistance exercises. Although the quadriceps muscles are functionally beneficial in CKD 33, future training interventions should also look to maintain the musculature of other lower limb muscles important for physical functioning (e.g., calf muscles).
Currently, no universally agreed method exists to estimate MCID. Although MCID values are dynamic and often context (and intervention) specific, 50 the most useful concept of MCID should indicate that a treatment is effective and alert the clinician or healthcare professional and the patient to its impact on patient's life. 26 Although an anchor-based method, which is patient centered, is perhaps the most pertinent approach to do this, it is important to remember that condemning an intervention because a group failed to meet the MCID may be misguided, because the weakness may be borne within the MCID rather than the intervention itself. 27 In an ideal world, adjunct metrics, such as the MDC along with statistical descriptive of variations (e.g., 95% CI, effect size), should be used alongside the MCID to help interpret and evaluate whole changes from an intervention.
Summary
We have established the MCID in a nondialysis CKD population for several commonly reported tests of physical function. These values represent the minimum change required for the patient to see noticeable and beneficial change on their overall health status. These scores will help rehabilitation professionals, clinicians, and researchers interpret "meaningful" changes after interventions such as renal exercise rehabilitation programs where these tests are commonly used. Furthermore, these MCIDs can be used to inform future trial methodology by estimating sample size to help power studies to detect clinically important changes over statistical ones.
